Literature DB >> 17296587

Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.

Hendrik-Tobias Arkenau, Geoff Chong, David Cunningham, David Watkins, Bhawna Sirohi, Ian Chau, Andrew Wotherspoon, Andy Norman, Alan Horwich, Estella Matutes.   

Abstract

Novel, effective therapies are needed for peripheral T-cell non-Hodgkin's lymphoma (PTCL). We treated 16 patients with a combination of gemcitabine, cisplatin and methylprednisolone (GEM-P). Three patients (19%) achieved a complete remission and eight (50%) a partial remission. GEM-P has encouraging efficacy with an acceptable toxicity profile in patients with PTCL.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17296587     DOI： 10.3324/haematol.10737

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  22 in total

Review 1.  Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?

Authors:  Carla Casulo; Steven Horwitz
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 2.  Novel therapies in peripheral T-cell lymphomas.

Authors:  Hilary M O'Leary; Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

Review 3.  Novel therapies in peripheral T-cell lymphomas.

Authors:  Hilary M O'Leary; Kerry J Savage
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

4.  Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond.

Authors:  Francine Foss
Journal:  Ther Adv Hematol       Date:  2011-06

5.  Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.

Authors:  Kein-Leong Yim; Sue Ashley
Journal:  Med Oncol       Date:  2012-07-24       Impact factor: 3.064

Review 6.  Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Kamel Laribi; Mustapha Alani; Catherine Truong; Alix Baugier de Materre
Journal:  Oncologist       Date:  2018-04-19

7.  Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.

Authors:  Shuyan Liu; Zhengang Yuan; Chunyang Zhang; Weijun Fu; Jian Hou
Journal:  Oncol Lett       Date:  2012-05-21       Impact factor: 2.967

8.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.

Authors:  Daruka Mahadevan; Joseph M Unger; Catherine M Spier; Daniel O Persky; Fay Young; Michael LeBlanc; Richard I Fisher; Thomas P Miller
Journal:  Cancer       Date:  2012-07-25       Impact factor: 6.860

9.  Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.

Authors:  Mei Dong; Xiao-Hui He; Peng Liu; Yan Qin; Jian-Liang Yang; Sheng-Yu Zhou; Sheng Yang; Chang-Gong Zhang; Lin Gui; Li-Qiang Zhou; Yuan-Kai Shi
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

10.  Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.

Authors:  Matthew A Lunning; Alison J Moskowitz; Steven Horwitz
Journal:  J Clin Oncol       Date:  2013-04-29       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.